STAT Plus: Telehealth is a ‘silver lining’ of the pandemic, but implementing it permanently won’t be easy
The coronavirus pandemic has stretched hospital resources beyond their capacity, disrupted the delivery of care,…
Category: STAT Plus
STAT Plus: California supports an attorney’s unusual whistleblower lawsuit against ‘fraudulent’ patents
The California insurance commissioner is supporting an unusual gambit by a patent attorney who filed…
STAT Plus: States file a third lawsuit accusing dozens of generic drug makers of price fixing
An ongoing probe by numerous states widened with a new lawsuit accusing more than two…
STAT Plus: A patient’s microbiome could have a major impact on how drugs affect them, new research confirms
The unique array of bacteria in a person’s gut can dramatically change how well they…
STAT Plus: ‘An extremely volatile time’: New report underscores the recent rollercoaster of the biotech market
A new report from BIO shows just how chaotic the last few years have been…
STAT Plus: Pharmalittle: Fauci encourages fair pricing for Covid-19 products; U.S. plans to start pivotal vaccine trials this summer
Good morning, everyone, and how are you today? The heat continues to rise higher here…
STAT Plus: Medical device startup raises almost $44M to advance a less-invasive treatment for fluid in the brain
A Massachusetts medical device startup said Tuesday it has raised $43.9 million in venture capital…
.jpg)
STAT Plus: Many Canadian medical societies fail to disclose industry funding in their clinical guidelines
Many Canadian medical societies and specially focused disease groups fail to disclose industry funding in…
STAT Plus: A judge rules AbbVie isn’t ‘immunized’ from antitrust claims over its Humira patent dealings
In a victory for AbbVie (ABBV), a U.S. federal judge ruled the drug maker did…
STAT Plus: Judge rules AbbVie didn’t unfairly thwart Humira competition with its ‘patent thicket’
In a victory for AbbVie (ABBV), a U.S. federal judge ruled the drug maker did…
STAT Plus: As biotech drifts from amyloid hypothesis for Alzheimers, some see reason to cling on
Two biotech CEOs are cautiously optimistic about the controversial amyloid hypothesis, which suggests a sticky…
STAT Plus: Pharmalittle: Compounders push to make pandemic changes permanent; production concerns seen for Covid-19 monoclonals
Hello, everyone, and how are you this fine, sunny morning? Here on the Pharmalot campus,…
STAT Plus: The coronavirus pandemic is reigniting a fierce debate over compounded drugs
In hopes of alleviating potential drug shortages and other issues wrought by the coronavirus pandemic,…
STAT Plus: Why would AstraZeneca want to buy Gilead? Some analysts say it’s not entirely clear
Amid intense interest in Gilead Sciences (GILD) thanks to its experimental Covid-19 drug, an out-of-left-field…
STAT Plus: The next record-setting IPO: a drug company that doesn’t develop drugs
Royalty Pharma, a business built on investing in other people’s medicines, is planning to raise…
STAT Plus: Pharmalittle: Will AstraZeneca bid for Gilead?; university terminates researcher over Covid-19 papers
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Sarepta’s gene therapy for limb-girdle disease shows improved muscle function after one year
Sarepta Therapeutics said Monday that three children born with a rare muscle-wasting disease called limb-girdle…
STAT Plus: Will the ‘patent dance’ cause Amgen to temporarily pull a biosimilar off the market?
In a closely watched case, a federal appeals court must decide whether a biosimilar company…
STAT Plus: China’s biggest-ever Nasdaq biotech IPO comes at an awkward time
Legend Biotech raised more than $400 million in a Nasdaq IPO on Friday, marking the…
STAT Plus: Startup developing an inhaler for seizures is acquired by UCB
A startup conceived to improve emergency treatment for epileptic seizures based on a father’s fears…
.jpg)
STAT Plus: Pharmalittle: Groups backed by pharma oppose equitable Covid-19 pricing; AstraZeneca strikes big Covid-19 vaccine deal
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Wholesale drug prices — and net prices — keep falling for most drugs
Amid continued political pressure on the pharmaceutical industry, a new analysis finds that brand-name drug…
STAT Plus: Inovio sues a key contract manufacturer as it races to develop a Covid-19 vaccine
As the race to develop a Covid-19 vaccine accelerates, Inovio Pharmaceuticals (INO) filed a lawsuit…
STAT Plus: Pharmalittle: Five Covid-19 vaccine makers chosen for Warp Speed project; Moderna CEO defends data release
Good morning, folks, and how are you today? We are doing just fine, thank you….
STAT Plus: In a first for RNA-modifying drugs, AstraZeneca partners with startup Accent Therapeutics
Drug giant AstraZeneca is moving deeper into RNA-based therapies with a new partnership with the…
STAT Plus: Recapping ASCO 2020, talking cancer therapy combinations, and looking to the future
Before it even started, ASCO 2020 was one for the books. Held virtually for the…
STAT Plus: Tiny Denmark saved lots of money on biosimilar Humira, while Americans are still paying big bucks
For those yearning for the day when biosimilars save the U.S. health care system huge…
STAT Plus: Private insurance might provide some shield from insulin price hikes — but the picture of costs is complicated
Although the cost of insulin has risen dramatically over the years and prompted a political…
STAT Plus: Moderna released scant Covid-19 data to prevent a leak, CEO says
The biotech company Moderna invited the scrutiny of the world last month when it withheld…
STAT Plus: Pharmalittle: FDA used ‘threadbare evidence’ to OK malaria drugs; GAO slams FDA’s supply-chain oversight, again
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT Plus: Lawmakers, government watchdog blast FDA for poor oversight of U.S. drug supply chain
WASHINGTON — A government watchdog blasted the Food and Drug Administration for fumbling its oversight…
STAT Plus: Innovent starts China’s first trial of a novel cancer immunotherapy
A version of this story appeared Tuesday in STAT China, a weekly guide to biopharma and…
STAT Plus: Pharmalittle: Stressed Americans cause a shortage of an antidepressant; Dems attack GOP candidates over malaria drug
Rise and shine, another busy day is on the way. And it feels particularly busy….
STAT Plus: Pfizer to invest up to $500M in public companies with drugs in the clinic
Pfizer, the world’s largest drug company, is going to try its hand at picking biotech…
STAT Plus: Despite protest, industry group backs use of horseshoe crab blood to test for bacteria in drugs
After a lengthy review, the organization that sets manufacturing standards for drug makers will keep…
STAT Plus: ASCO 2020 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress
The annual meeting American Society of Clinical Oncology (ASCO) concluded on Sunday. The closely-followed cancer…
STAT Plus: Pharmalittle: Fauci ‘didn’t like’ Moderna vaccine data release; Pfizer breast cancer drug suffers a setback
Good morning, everyone, and welcome to another working week. We hope the weekend respite, if…
New research offers hope for a way through the blood-brain barrier, ‘the final frontier for drug delivery’
We’ve evolved elegant protections for our brains. Gray matter deftly avoids contact with most interlopers,…
STAT Plus: Pharmalittle: Administration mishandled initial remdesivir distribution; AstraZeneca lung cancer drug shows big benefit
And so, another working week will soon draw to a close. Not a moment, too…
STAT Plus: Additional blood cancer responses seen with Allogene’s off-the-shelf CAR-T cells, updated study shows
Allogene on Friday released updated results from the first study of its off-the-shelf CAR-T cell…
STAT Plus: Despite economic downturn, big names in health tech are drawing in significant funding
It was expected to be a last-minute salvo: As much of the world braced for…
STAT Plus: AstraZeneca study results could change treatment for certain early-stage lung cancer patients
In April, AstraZeneca halted a clinical trial of its genetically targeted lung cancer drug Tagrisso…
STAT Plus: Bacteria are widespread in tumors, forming distinct populations depending on the cancer type
In what outside experts called the most rigorous and comprehensive survey of bacteria in human…
STAT Plus: Pharmalittle: Glaxo aims for 1 billion doses of a Covid-19 vaccine booster; Pence aide holds lots of pharma stocks
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT Plus: FDA finds ‘unacceptable’ levels of a possible carcinogen in a widely used diabetes pill
After months of testing, the Food and Drug Administration reported finding unacceptable levels of a…
STAT Plus: Medical societies have ‘extensive’ financial ties with drug and device makers
Many leaders of influential medical societies have extensive financial relationships with drug and device makers,…
STAT Plus: Vertex angers U.K. cystic fibrosis patients with a delay in submitting data for its newest therapy
Vertex Pharmaceuticals (VRTX) has sparked a new round of anger among cystic fibrosis patients in…
STAT Plus: Pharmalittle: Moderna executives cashed out big time; should we have ‘quality scores’ for manufacturing drugs?
Hello, everyone, and how are you today? We are coping so far, thank you. Despite…
STAT Plus: Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it
Q32 Bio has two targets in its sights: the two arms of the immune system….
STAT Plus: Scientists 3D-map the ‘little brain of the (rat) heart’
Even cardiologists might not know — or pay attention to — the intracardiac nervous system….